112 related articles for article (PubMed ID: 8175282)
1. Effects of recombinant human erythropoietin on sodium balance in nondialysed children with chronic renal failure.
Kavukçu S; Saatci U; Ciliv G; Söylemezoğlu O; Bakkaloğlu A; Besbas N; Ozen S
Int Urol Nephrol; 1993; 25(6):611-5. PubMed ID: 8175282
[TBL] [Abstract][Full Text] [Related]
2. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
[TBL] [Abstract][Full Text] [Related]
3. [Single weekly dose of recombinant erythropoietin in children with chronic renal insufficiency].
Guízar JM; Gutiérrez MJ; Sánchez G; Kornhauser C
Rev Invest Clin; 1996; 48(3):173-7. PubMed ID: 8966377
[TBL] [Abstract][Full Text] [Related]
4. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
[TBL] [Abstract][Full Text] [Related]
5. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin (rhEPO) treatment potentiates growth hormone (GH) response to growth hormone releasing hormone (GHRH) stimulation in hemodialysis patients.
Cremagnani L; Cantalamessa L; Orsatti A; Vigna L; Vallino F; Buccianti G
Clin Nephrol; 1993 May; 39(5):282-6. PubMed ID: 8513607
[TBL] [Abstract][Full Text] [Related]
7. Effects of recombinant human erythropoietin on hematopoietic progenitors of chronic hemodialysis patients in vitro and in vivo.
Hino M; Miyazono K; Urabe A; Takaku F
Int J Cell Cloning; 1989 Jul; 7(4):257-63. PubMed ID: 2768843
[TBL] [Abstract][Full Text] [Related]
8. Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study.
Faller B; Slingeneyer A; Waller M; Michel C; Grützmacher P; Müller HP; Barany P; Grabensee B; Issad B; Schmitt H
Clin Nephrol; 1993 Sep; 40(3):168-75. PubMed ID: 8403573
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of renal anemia with recombinant human erythropoietin].
Burghard R; Gordjani N; Leititis JU
Monatsschr Kinderheilkd; 1989 Mar; 137(3):174-7. PubMed ID: 2716749
[TBL] [Abstract][Full Text] [Related]
10. Effect of erythropoietin treatment on tissue oxygenation in patients with severe transfusion dependent renal anaemia.
Landgraf H; Grützmacher P; Garcia-Bartels C; Bergmann M; Ehrly AM; Schoeppe W
Eur J Med; 1993; 2(7):393-7. PubMed ID: 8258026
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin in renal transplant recipients with renal anemia.
Traindl O; Barnas U; Franz M; Falger S; Klauser R; Kovarik J; Graf H
Clin Transplant; 1994 Feb; 8(1):45-8. PubMed ID: 8136567
[TBL] [Abstract][Full Text] [Related]
12. In vivo effects of recombinant human erythropoietin on bone marrow hematopoiesis in patients with chronic renal failure.
Biljanović-Paunović L; Djukanović L; Lezaić V; Stojanović N; Marisavljević D; Pavlović-Kentera V
Eur J Med Res; 1998 Dec; 3(12):564-70. PubMed ID: 9889177
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
14. [Rapid, progressive deterioration of renal function following erroneous administration of high doses of subcutaneous recombinant erythropoietin].
Buemi M; Allegra A; Aloisi C; Corica F; Frisina N
Riv Eur Sci Med Farmacol; 1996; 18(1):39-42. PubMed ID: 8766781
[TBL] [Abstract][Full Text] [Related]
15. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
16. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
17. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
18. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
20. [Human recombinant erythropoietin in treatment of uremic anemia in children with continual ambulatory peritoneal dialysis].
Litwin M; Boguszewska-Baczkowska A; Jelonek A
Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):135-6. PubMed ID: 8090665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
